Kanabinoidi in Covid-19
Covid-19 disease is spreading rapidly around the world. It is an infectious disease caused by the Sars-CoV2 virus and is spread mainly by respiratory droplets, which are spread by infected people when they cough and sneeze. The time from infection to the onset of symptoms (virus incubation period) lasts 5-6 days, and symptoms appear up to 12 days after infection. Spread can be very well limited by hand washing and disinfection and other hygiene measures.
The infection caused by the virus can be very problematic for some people, and even fatal for some, and a good part of the population gets over it without any special symptoms or in a milder form. Typical symptoms are fever, cough, shortness of breath, muscle aches, fatigue, loss of smell and taste, etc. The infection can progress to pneumonia and acute respiratory distress syndrome. The emphasis in treatment is primarily on relieving symptoms. In the very serious course of the disease, respiratory, renal and septic shock failure can occur, resulting in death. Acute heart injuries have been reported among some hospitalized patients.
Patients usually recover within a few weeks, but for some people the long-term consequences of the disease are possible, among which anxiety and depression, fatigue, shortness of breath and acute pain stand out.
The first official Covid-19 case was detected in November 2019 in China in the city of Wuhan, the capital of Hubei Province, from where it spread with lightning speed around the world. The World Health Organization declared a pandemic on March 11, 2020.
How can we help ourselves with cannabis and cannabinoids?
In 2020, scientists around the world began researching Covid19. Since the scope of cannabis and cannabinoids in recent years became popular and very well-researched and professionally evaluated, some of the research became dedicated to the link between cannabinoids and the Sars-CoV2 virus and the disease Covid19.
In a study from 2021 Nguyen and colleagues described that CBD can block Sars-CoV2 infection in the early stages of infection and that cannabinoid use is associated with a lower risk of infection, and that the active compound 7-OH-CBD, which is the same metabolite that is also involved in the treatment of epilepsy with CBD. They described a significant reduction in the risk of virus infection in patients taking CBD. Although many CBD formulations are available on the market, they vary widely in quality, quantity, and pharmacokinetic properties after oral administration.
In an article from 2020, Esposito and his colleagues investigated the impact of potential pandemic diseases cannabidiol Covid19. Phytocannabinoid CBD is one of the most interesting molecules in the field of pharmacology, as it has a wide range of therapeutic effects, among which are proven anticonvulsant, sedative, hypnotic, antipsychotic, anti-cancer, anti-inflammatory and neuroprotective. It is believed that cannabidiol and other cannabinoids promising drug candidates, which could bet on the encouraging preclinical studies. Further research and evidence will be needed to confirm the beneficial properties in the use of cannabinoids for the treatment of Covid-19 disease.
In a 2021 study, Raj and colleagues investigated the antiviral properties of cannabinoids against the virus using computer simulations and an in vitro approach. They performed a structured review of various cannabinoids because they directly or indirectly activate the CB2 receptor and weaken the properties of inflammatory cytokines. Based on a computer study and the in vitro antiviral potentials of CBD and d9-THC against Sars-CoV2, it was concluded that both molecules can inhibit the virus in two ways. The molecules can bind to and inhibit SARS-CoV-2 M pro , leading to blockage of the translation process and reduction of inflammatory cytokine levels in lung cells by acting as a CB2 receptor agonist. Thus, CBD and d9-THC can be used in combination with each other or with other drugs to treat patients with Covid-19.
In addition to the above-mentioned research and studies, a large number of articles are available exploring the effects and possibilities of using cannabinoids to alleviate the course of the disease, as a preventive protection, and as a successful aid in the treatment and elimination of consequences after illness.
How can we help ourselves with Hempethica products?
In our company, we have focused on the development of different cannabinoid drops with different properties which is based on the terpene profile in each cannabis plant. The correct terpene and cannabis profile can relieve symptoms and help with recovery. We suggest using hemp drops for better well-being , which take care of our endocannabinoid system, which regulates our immune system and thus makes us feel better. The drops can also be taken preventively to help and improve our immune system.
- Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, Sarnelli G. The potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol. 2020 Nov;177(21):4967-4970. Link/DOI: 1111/bph.15157. Epub 2020 Jul 16. PMID: 32519753; PMCID: PMC7300643.
- Nguyen LC, Yang D, Nicolaescu V, Best TJ, Ohtsuki T, Chen SN, Friesen JB, Drayman N, Mohamed A, Dann C, Silva D, Gula H, Jones KA, Millis JM, Dickinson BC, Tay S, Oakes SA, Pauli GF, Meltzer DO, Randall G, Rosner MR. Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response. bioRxiv [Preprint]. 2021 Mar 10:2021.03.10.432967. Link/DOI: 1101/2021.03.10.432967. PMID: 33758843; PMCID: PMC7987002.
- Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12593-12608. Link/DOI: 26355/eurrev_202012_24057. PMID: 33336780.
- Tahamtan A, Tavakoli-Yaraki M, Salimi V. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients. Expert Rev Respir Med. 2020 Oct;14(10):965-967. Link/DOI: 1080/17476348.2020.1787836. Epub 2020 Jun 30. PMID: 32576053; PMCID: PMC7441794.
- Raj V, Park JG, Cho KH, Choi P, Kim T, Ham J, Lee J. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. Int J Biol Macromol. 2021 Jan 31;168:474-485. Link/DOI: 1016/j.ijbiomac.2020.12.020. Epub 2020 Dec 5. PMID: 33290767; PMCID: PMC7836687.
- Wikipedia, link